The packet lists no associated genes for this condition and does not list an inheritance pattern. The packet does not certify a specific cause or a molecular mechanism, so none is described here. Absence of this information in the packet is not a statement that no cause or genetic contribution is known.

The packet does not include diagnostic methods, diagnostic criteria, or newborn screening information for this condition, so how the condition is identified is not certified here. Among the phenotype annotations, monoclonal immunoglobulin M proteinemia is annotated as a very frequent feature (80-99%), and the packet lists lymphoplasmacytic lymphoma with IgM gammopathy as a synonym. The packet does not link these entries to a diagnostic process.

The packet contains no GeneReviews management text and no foundational therapy list for this condition. It does contain US Food and Drug Administration records.

Two products have active market status in the FDA records in the packet: BRUKINSA (zanubrutinib), with a new drug application approval dated 2025-06-10, and IMBRUVICA (ibrutinib), with a new drug application approval dated 2022-08-24. The orphan drug records in the packet list Imbruvica and Brukinsa as approved, with indications naming Waldenstrom's macroglobulinemia. Doses, schedules, and interactions are not part of the packet and are not described.

The orphan drug records also list a number of products with designated status, including sonrotoclax, acalabrutinib, idelalisib, mavorixafor, and oprozomib, along with several investigational molecules and a CD20-directed CAR T-cell product. A designation is a regulatory status for a product under development and is not an approval. One everolimus record has withdrawn status.

The packet notes that patient assistance programs may be available; one program listing is present for this condition, and details are not reproduced here.

The packet does not include natural history information or a GeneReviews clinical description for this condition. Prognosis is not certified in this packet, and no statement about disease course, survival, or outcomes is made here.

The packet records ClinicalTrials.gov entries for this condition, and all of the entries counted are active. Many active records are present, and the packet provides a search link for the full list. The intervention types across these records include drug therapy, biologic therapy, procedural interventions, and other interventions, and the sponsor profile is described as mixed. The packet flags that gene therapy trials are present among the records.

Examples of listed records include a study comparing venetoclax with rituximab against ibrutinib with rituximab or zanubrutinib alone (NCT04840602, recruiting), a study of epcoritamab as consolidative therapy after treatment with a Bruton tyrosine kinase inhibitor (NCT07882173, not yet recruiting), and a dose escalation and expansion study of MDX2003 in several lymphoma types (NCT07249905, recruiting). Some listed records are broader sample collection or hematologic cancer characterization studies rather than studies specific to this condition.

The packet's publication summary classifies a body of literature in which case reports and case series form the largest category, followed by reviews, and it flags the presence of biomarker publications and recent trial publications.